v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as one reportable segment in the United States, which includes all activities related to the development and commercialization of its DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases.
The Company's Chief Executive Officer (CEO) is its Chief Operating Decision Maker (CODM), responsible for allocating resources and assessing Company performance using aggregated financial information. Utilizing aggregated financial information enables the CODM to determine the most appropriate resource allocation across the organization, research and development projects or other initiatives consistent with the Company's corporate objectives. The CODM primarily uses total net loss as reported on the statements of operations and comprehensive loss to measure segment loss, supplemented by certain additional significant expense details reflected in the table below. The measure of segment assets is reported on the consolidated balance sheet as total assets.
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended March 31,
20262025
Revenue from collaborative arrangement$— $65,343 
Less:
Research and development:
     INO-31074,005,292 3,507,342 
     INO-3112 and other Immuno-oncology365,228 684,449 
     Other research and development programs (a)1,083,283 738,060 
     Engineering and device-related4,041,116 5,061,810 
     Stock-based compensation276,912 553,394 
     Other unallocated expenses 4,298,276 5,545,847 
General and administrative7,879,886 9,024,970 
Total operating expenses21,949,993 25,115,872 
Interest income439,593 808,077 
Change in fair value of common stock warrant liabilities4,137,703 3,712,872 
(Loss) gain on investment in affiliated entity(2,103,688)695,131 
Net unrealized gain on available-for-sale equity securities79,077 140,234 
Other expense, net(285,490)(482)
Net loss$(19,682,798)$(19,694,697)
(a) Includes DMAb, DPROT and other research and development programs, net of contributions received from grant agreements and recorded as contra-research and development expense.